Randomized comparison of 9-month stent strut coverage of
biolimus and everolimus drug-eluting stents assessed by optical
coherence tomography in patients with ST-segment elevation
myocardial infarction. Long-term (5-years) clinical follow-up
(ROBUST trial)

J 2023

Randomized comparison of 9-month stent strut coverage of biolimus and everolimus drug-eluting stents assessed by optical coherence tomography in patients with ST-segment elevation myocardial infarction. Long-term (5-years) clinical follow-up (ROBUST trial)

JAKL, Martin, Pavel CERVINKA, Jan KAŇOVSKÝ, Petr KALA, Martin POLOCZEK et. al.

Základní údaje

Originální název

Randomized comparison of 9-month stent strut coverage of biolimus and everolimus drug-eluting stents assessed by optical coherence tomography in patients with ST-segment elevation myocardial infarction. Long-term (5-years) clinical follow-up (ROBUST trial)

Autoři

JAKL, Martin (203 Česká republika), Pavel CERVINKA (203 Česká republika, garant), Jan KAŇOVSKÝ (203 Česká republika, domácí), Petr KALA (203 Česká republika), Martin POLOCZEK (203 Česká republika), Michaela CERVINKOVA (203 Česká republika), Hiram G BEZERRA, Zdenek VALENTA (203 Česká republika) a Marco Aurelio COSTA

Vydání

CARDIOLOGY JOURNAL, GDANSK, VIA MEDICA, 2023, 1897-5593

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30201 Cardiac and Cardiovascular systems

Stát vydavatele

Polsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 2.900 v roce 2022

Kód RIV

RIV/00216224:14110/23:00133406

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.5603/CJ.a2023.0013

UT WoS

001116942600001

Klíčová slova anglicky

drug-eluting stent; primary percutaneous coronary intervention; stent strut coverage; optical coherence tomography; ST-segment elevation myocardial infarction; clinical trials

Štítky

14110211, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 2. 2. 2024 09:51, Mgr. Tereza Miškechová

Anotace

V originále

Background: The aim of the study was to compare healing (assessed by optical coherence tomography [OCT]) of biolimus A9 (BES) and everolimus drug-eluting stents (EES) at 9-month follow-up in patients with ST-segment elevation myocardial infarction (STEMI) treated by primary percutaneous coronary intervention (pPCI). Nine-month clinical and angiographic data were also compared in both groups as well as clinical data at 5 years of follow-up.Methods: A total of 201 patients with STEMI were enrolled in the study and randomized either to pPCI with BES or EES implantation. All patients were scheduled for 9 months of angiographic and OCT follow-up.Results: The rate of major adverse cardiovascular events (MACE) was comparable at 9 months in both groups (5% in BES vs. 6% in the EES group; p = 0.87). Angiographic data were also comparable between both groups. The main finding at 9-month OCT analysis was the greatly reduced extent of mean neointimal area at the cost of a higher proportion of uncovered struts in the BES group (1.3 mm2 vs. 0.9 mm2; p = 0.0001 and 15.9% vs. 7.0%; p = 0.0001, respectively). At 5 years of clinical follow-up the rate of MACE was comparable between both groups (16.8% vs. 14.0%, p = 0.74).Conclusions: The study demonstrates a very low rate of MACE and good 9-month stent strut coverage of second-generation BES and EES in patients with STEMI. BES showed greatly reduced extent of mean neointimal hyperplasia area at the cost of a higher proportion of uncovered struts when compared to EES. The rate of MACE was low and comparable in both groups at 5 years. (Cardiol J 2023; 30, 6: 921-928)

Citovat

JAKL, Martin, Pavel CERVINKA, Jan KAŇOVSKÝ, Petr KALA, Martin POLOCZEK, Michaela CERVINKOVA, Hiram G BEZERRA, Zdenek VALENTA a Marco Aurelio COSTA. Randomized comparison of 9-month stent strut coverage of biolimus and everolimus drug-eluting stents assessed by optical coherence tomography in patients with ST-segment elevation myocardial infarction. Long-term (5-years) clinical follow-up (ROBUST trial). CARDIOLOGY JOURNAL. GDANSK: VIA MEDICA, 2023, roč. 30, č. 6, s. 921-928. ISSN 1897-5593. Dostupné z: https://dx.doi.org/10.5603/CJ.a2023.0013.

@article{2368963,
   author = {Jakl, Martin and Cervinka, Pavel and Kaňovský, Jan and Kala, Petr and Poloczek, Martin and Cervinkova, Michaela and Bezerra, Hiram G and Valenta, Zdenek and Costa, Marco Aurelio},
   article_location = {GDANSK},
   article_number = {6},
   doi = {http://dx.doi.org/10.5603/CJ.a2023.0013},
   keywords = {drug-eluting stent; primary percutaneous coronary intervention; stent strut coverage; optical coherence tomography; ST-segment elevation myocardial infarction; clinical trials},
   language = {eng},
   issn = {1897-5593},
   journal = {CARDIOLOGY JOURNAL},
   title = {Randomized comparison of 9-month stent strut coverage of biolimus and everolimus drug-eluting stents assessed by optical coherence tomography in patients with ST-segment elevation myocardial infarction. Long-term (5-years) clinical follow-up (ROBUST trial)},
   url = {https://journals.viamedica.pl/cardiology_journal/article/view/90905},
   volume = {30},
   year = {2023}
}

TY  - JOUR
ID  - 2368963
AU  - Jakl, Martin - Cervinka, Pavel - Kaňovský, Jan - Kala, Petr - Poloczek, Martin - Cervinkova, Michaela - Bezerra, Hiram G - Valenta, Zdenek - Costa, Marco Aurelio
PY  - 2023
TI  - Randomized comparison of 9-month stent strut coverage of biolimus and everolimus drug-eluting stents assessed by optical coherence tomography in patients with ST-segment elevation myocardial infarction. Long-term (5-years) clinical follow-up (ROBUST trial)
JF  - CARDIOLOGY JOURNAL
VL  - 30
IS  - 6
SP  - 921-928
EP  - 921-928
PB  - VIA MEDICA
SN  - 18975593
KW  - drug-eluting stent
KW  - primary percutaneous coronary intervention
KW  - stent strut coverage
KW  - optical coherence tomography
KW  - ST-segment elevation myocardial infarction
KW  - clinical trials
UR  - https://journals.viamedica.pl/cardiology_journal/article/view/90905
N2  - Background: The aim of the study was to compare healing (assessed by optical coherence tomography [OCT]) of biolimus A9 (BES) and everolimus drug-eluting stents (EES) at 9-month follow-up in patients with ST-segment elevation myocardial infarction (STEMI) treated by primary percutaneous coronary intervention (pPCI). Nine-month clinical and angiographic data were also compared in both groups as well as clinical data at 5 years of follow-up.Methods: A total of 201 patients with STEMI were enrolled in the study and randomized either to pPCI with BES or EES implantation. All patients were scheduled for 9 months of angiographic and OCT follow-up.Results: The rate of major adverse cardiovascular events (MACE) was comparable at 9 months in both groups (5% in BES vs. 6% in the EES group; p = 0.87). Angiographic data were also comparable between both groups. The main finding at 9-month OCT analysis was the greatly reduced extent of mean neointimal area at the cost of a higher proportion of uncovered struts in the BES group (1.3 mm2 vs. 0.9 mm2; p = 0.0001 and 15.9% vs. 7.0%; p = 0.0001, respectively). At 5 years of clinical follow-up the rate of MACE was comparable between both groups (16.8% vs. 14.0%, p = 0.74).Conclusions: The study demonstrates a very low rate of MACE and good 9-month stent strut coverage of second-generation BES and EES in patients with STEMI. BES showed greatly reduced extent of mean neointimal hyperplasia area at the cost of a higher proportion of uncovered struts when compared to EES. The rate of MACE was low and comparable in both groups at 5 years. (Cardiol J 2023; 30, 6: 921-928)
ER  -

JAKL, Martin, Pavel CERVINKA, Jan KAŇOVSKÝ, Petr KALA, Martin POLOCZEK, Michaela CERVINKOVA, Hiram G BEZERRA, Zdenek VALENTA a Marco Aurelio COSTA. Randomized comparison of 9-month stent strut coverage of biolimus and everolimus drug-eluting stents assessed by optical coherence tomography in patients with ST-segment elevation myocardial infarction. Long-term (5-years) clinical follow-up (ROBUST trial). \textit{CARDIOLOGY JOURNAL}. GDANSK: VIA MEDICA, 2023, roč.~30, č.~6, s.~921-928. ISSN~1897-5593. Dostupné z: https://dx.doi.org/10.5603/CJ.a2023.0013.

Podrobný výpis o publikaci